Quarterly report pursuant to Section 13 or 15(d)

Income taxes

v3.7.0.1
Income taxes
6 Months Ended
Jun. 30, 2017
Income Tax Disclosure [Abstract]  
Income taxes

4. Income taxes

During the three months ended June 30, 2017 and the six months ended June 30, 2017 the Company recorded income tax expenses of $0.8 million and $0.8 million, respectively, representing an effective tax rate of (4.71%). The income tax expense is related the Company´s Australian jurisdiction, net of loss carryforwards resulting from taxable income from the AstraZeneca Agreements.